Boston MA 胶质瘤临床试验
20项针对 胶质瘤的研究正在 Boston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
MCT for the Harvard/UCSF ROBIN Center
招募中
- Brigham and Women's Hospital, Boston
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
招募中1/2 期
- Dana-Farber Cancer Institute, Boston
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
招募中2 期
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
招募中1/2 期
- Dana Farber Cancer Institute., Boston
Targeted Pediatric High-Grade Glioma Therapy
招募中观察性研究
- Dana-Farber Cancer Institute, Boston
Study of Olutasidenib and Temozolomide in HGG
招募中2 期
- Susan Chi, Boston
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
招募中3 期
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma
招募中2 期
- Dana-Farber Cancer Institute, Boston
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
招募中1/2 期
- Research Site, Boston
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
招募中2 期
- Tufts Medical Center, Boston
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
CARv3-TEAM-E T Cells in Glioblastoma
招募中1 期
- Massachusetts General Hospital Cancer Center, Boston
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
招募中早期 I 期欢迎健康志愿者
- Dana-Farber Cancer Institute, Boston
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
招募中2 期
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
招募中1/2 期
- Dana Farber Cancer Institute, Boston
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion
招募中早期 I 期
- Dana-Farber Cancer Institute, Boston
rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG
招募中1 期
- Dana-Farber Boston Children's Cancer and Blood Disorders Center, Boston
CUE-102 in Recurrent Glioblastoma
招募中1 期
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
NeuroPathways Intervention for Brain Tumor Patients
招募中
- Massachusetts General Hospital Cancer Center, Boston
ASCENT Intervention for Brain Tumor Patients
招募中
- Massachusetts General Hospital Cancer Center, Boston
The SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)
招募中观察性研究
- Massachusetts General Hospital, Boston
其他城市的 胶质瘤试验
- New York City, NY25 项研究
- Houston, TX23 项研究
- Washington, DC19 项研究
- Philadelphia, PA16 项研究
- Miami, FL15 项研究
- Columbus, OH15 项研究
- San Francisco, CA14 项研究
- Chicago, IL13 项研究
- Durham, NC12 项研究
- Seattle, WA11 项研究
- Los Angeles, CA10 项研究
- St. Louis, MO10 项研究
Boston的其他研究
- 乳腺癌111 项研究
- 非小细胞肺癌90 项研究
- 癌症（所有类型）86 项研究
- 结直肠癌63 项研究
- 转移性癌症63 项研究
- 肺癌62 项研究
- 卵巢癌61 项研究
- 前列腺癌59 项研究
- 抑郁症52 项研究
- 子宫内膜癌50 项研究
- 心力衰竭44 项研究
- 急性髓系白血病44 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月5日。每项研究自行设定入选标准，由研究团队决定谁能参与。